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This paper is about a way of correction of endothelial dysfunction with the inhibitor of arginase: L-norvaline. There is an
imbalance between vasoconstriction and vasodilatation factors of endothelium on the basis of endothelial dysfunction. Among
vasodilatation agents, nitrogen oxide plays the basic role. Amino acid L-arginine serves as a source of molecules of nitrogen oxide
in an organism. Because of the high activity of arginase enzyme which catalyzes the hydrolysis of L-arginine into ornithine and
urea, the bioavailability of nitrogen oxide decreases. The inhibitors of arginase suppress the activity of the given enzyme, raising
and production of nitrogen oxide, preventing the development of endothelial dysfunction.
1.Introduction
The reasons and pathogenesis of cardiovascular diseases have
always been the object of steadfast attention as the given
pathology remains a principal cause of death rate of people.
The list of the most frequent diseases of heart and vessels
include ischemic illness of heart, arterial hypertension, cere-
brovascular diseases. In the pathogenesis of these disorders,
the basic role belongs to endothelial dysfunction [1].
Endothelial dysfunction is the ﬁrst stage of development
of heart and vessel illnesses. It is known that endothelium
is capable of excreting factors of vasodilatation which relax
smooth muscles of a vascular wall and lead to vasodilatation.
On the other hand, there are endothelium factors of
vasoconstriction. As a whole, on endothelial dysfunction,
an imbalance between these factors production and vaso-
constriction agents’ prevalence takes place [2]. In addition
endothelial dysfunction, which can lead to the breakdown of
the blood-brain barrier and impair cerebral autoregulation
and prothrombotic changes, is believed to be important in
mediating leukoaraiosis. The normal cerebral endothelium
plays a crucial role in the regulation of cerebral blood
ﬂow and autoregulation and in the blood-brain barrier.
In addition, in health, it presents an anticoagulant pheno-
type to blood. Upon stimulation by numerous agents, the
endothelium undergoes changes that allow it to participate
in the inﬂammatory response; this is known as endothelial
cell activation (ECA) [3]. One of the changes of ECA
is increased vascular permeability, and it is thought that
the entry of serum proteins into the vascular wall and
perivascular neural parenchyma may produce toxic eﬀects
[4].
Endothelial dysfunctions may also give rise to molecular
events involving a shift in the O(2) and CO(2) traﬃcking
system in the red blood cells, which will result in special
complex microcirculation disturbances in the white matter
of the brain [5]. Also slight chronic hypoperfusion or an
endothelial dysfunction may lead indirectly to a malfunction
of the molecular crosstalk between the nucleus and the
mitochondria [6].2 International Journal of Hypertension
The basic vasodilatation agent is considered to be a
molecule of nitrogen oxide (NO). Diﬀerently, endothelial
dysfunction is infringement of NO synthesis. In normally
functioning endothelium, there is a constant NO production
with the help of endothelial NO synthase (eNOS) from
L-arginine. It refers to group of semi-irreplaceable amino
acids and plays an important role in organism vital activity.
Not so long ago it has been established that L-arginine
is the predecessor of the NO possessing a wide spectrum
of bioregulation inﬂuences. NO production infringement
on endothelial dysfunctions is associated with reduction of
availabilityofL-arginine stocksforeNOS,accelerationofNO
metabolism, or a combination of both [7]. Thus, the basic
sourceof NOis L-arginine which arrives in an organism with
food. Because of the high activity of arginase—the enzyme
destroying L-arginine in a mucous membrane of thin
intestine, 40% of arginine arriving with food is destroyed in
the course of absorption, and its remaining quantity arrives
into a portal vein. Accepting the fact that 90% of L-arginine
is connect with protein , it is possible to consider that only
50% of alimentary arginine goes into system circulation.
The arginase is an enzyme of urea cycle that hydrolyzes L-
arginine to ornithine and urea. There are two isoforms of
this enzyme. Arginase I is constitutive, and “extrahepatic”
arginase (arginase II) is induced in vessel endothelium cells
by lipopolysaccharides and interferon.
An other way of L-arginine catabolism proceeds with the
formation of NO and citrulline. This process is catalyzed
by another enzyme—NO synthase (NOS)—which exists in
three isoforms: two constitutive, endothelial (eNOS) and
neuronal (nNOS), and one induced (iNOS). They carry
out the joining of molecular oxygen to nitrogen atom from
terminal guanidine group of L-arginine. In the regulation of
cardiovascular system, eNOS plays a leading role. Arginase
and NOS compete for a common substratum—L-arginine.
However, activity of arginase exceeds NOS activity by
thousand times. Hence, basic part of L-arginine turns into
ornithine and urea, thereby creating NO deﬁciency. In turn
the lack of NO, as already has been mentioned earlier, leads
to the development of endothelial dysfunction and to an
increase of cardiovascular pathology developmentrisk.
Thus, there is obviously a necessity of suppressing high
activity of arginase the decrease to risk and frequency of
development of illnesses of heart and vessels. With that aim
now arginase inhibitors of substances of a natural origin
[8] are investigated. Among substances of this group, L-
norvaline attracts the greatest interest, being nonselective
inhibitor of arginase which is able to suppress activity of
given enzyme, to raise endogenous stocks of L-arginine,
and also to increase production of NO, promoting normal
functioning of vessels endothelium [9].
The purpose of the present research was studying L-nor-
valine endothelium-protective properties in L-NAME- and
hyperhomocysteinemin-induced endothelial dysfunction.
2.Materialsand Methods
Experiments were led on white rat males of Wistar line in
mass of 200–250 grams.
NO synthase blocker, N-nitro-L-arginine methyl ester
(L-NAME), was inducted intraperitoneally (i.p.) in a dose
of 25mg/kg/day, once a day for 7 days. For simulation
of hyperhomocysteinemia, an amino acid methionine was
given intragastrically in a dose of 3g/kg/day once a day for 7
days. A solution of methionine is intragastrically introduced
ex tempore with polysorbate Tween-80 and 1% starch
solution. The data gained from intragastric introductionof
an equivalent amount of polysorbate solution Tween-80 was
used as control.
L-norvaline was given i.p. in a dose of 10mg/kg once a
day for 7 days.
Animals have been partitioned into groups, each includ-
ing 10 rats: (1) intact, (2) Tween-80; (3) L-NAME, (4)
methionine, (5) L-NAME + L-norvaline 10mg/kg, and (6)
methionine + L-norvaline 10mg/kg.
On the day 8 from the initiation of experiments under
anaesthetic (chloral hydrate 300mg/kg), a catheter in the
left carotid artery for recording of indexes of blood pressure
(BP) was entered. Bolus introduction of pharmacologi-
cal agents was made into a femoral vein. Hemodynamic
indexes were the systolic arterial pressure (SAP), a dias-
tolic arterial pressure (DAP), and cardiac contraction rate
metered continuously with a hardware-software complex
“Biopac”. Besides BP measuring, a series of the functional
trials was led in introduced succession: (1) endothelium-
dependent vasorelaxation test (intravenous entering of a
solution of acetylcholine (AH) in a dose of 40mkg/kg);
(2) endothelium-independent vasorelaxation test (intra-
venous entering of a solution of sodium nitroprusside (NP)
in a dose of 30mkg/kg) [10–12].
L e v e lo fe n d o t h e l i a ld y s f u n c t i o ni nt h ee x p e r i m e n t a l
animals and also the level of its correction by researched
drugs were valued on coeﬃcient of endothelial dysfunction
(CED).Thiscoeﬃcientrisobtainedbythefollowingformula:
CED = SBPNP/SBPAH,w h e r eS B P NP is the area of triangle
above a BP recovery curve at a functional test with NP
enteringandSBPAHisthear eaoftriangleabo v eaBPr ec o v ery
curve at a functional test with AH entering. Points of a
smaller cathetus of this triangle are the points of BP before
the test and a point of maximum reduction of a BP, and the
bigger cathetus is the time of BP restoration [10–12].
The results were expressed as the mean (M) ± the
standard error of mean (m). Diﬀerences were considered
signiﬁcant at P<. 05.
3.Results
NOS blockade caused by a seven-day introduction of L-
NAME led to an arterial hypertension (SAP: 190,3 ±
6,7mmhg, DAP: 145,0 ± 3,9mmhg). Simultaneous L-
NAME and L-norvaline introduction did not lead to a
decrease in indicators of BP reference values (Table 1). Daily
introduction of methionine under the designated scheme
did not cause authentic change of arterial pressure (Table 2).
Introduction of L-norvaline i.p. also did not inﬂuence
indicators of haemodynamics (Table 1).
For objectiﬁcation of endothelial dysfunction correction
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Table 1: Dynamics of blood pressure indicators on modeling of NO deﬁciency and its correction with L-norvaline (M ± m, n = 10).
Groups of animals Functional tests SAP, mmhg DAP, mmhg Area of vascular reaction CED
Intact
Before test 137,7 ± 3,7 101,9 ± 4,3
1,1 ± 0,1 AH 84,3 ± 4,5 38,7 ± 2,8 1268,0 ± 74,8
NP 83,0 ± 3,7 42,1 ± 4,4 1375,3 ± 93,7
L-NAME 25mg/kg
Before test 190,3 ± 6,7∗ 145,0 ± 3,9∗
5,4 ± 0,6∗ AH 110,6 ± 5,2∗ 82,8 ± 6,6∗ 695,3 ± 87,6∗
NP 88,7 ± 4,7 50,8 ± 4,2 3322,7 ± 116,7∗
L-NAME 25mg/kg + L-norvaline 10mg/kg
Before test 180 ± 4,7∗ 144,6 ± 10,2∗
2,1 ± 0,2∗∗ AH 106,7 ± 4,9∗ 56,1 ± 1,8∗ 1360,6 ± 126,9∗
NP 129,3 ± 5,1∗∗ 64,6 ± 2,5∗∗ 2827,2 ± 429,1∗∗
∗P<. 05 in comparison with intact group of animals; ∗∗P<. 05 in comparison with L-NAME group.
Table 2: Inﬂuence of methionine and L-norvaline on indicators of haemodynamics and coeﬃcient of endothelial dysfunction in modeling
of the homocysteine-induced NO deﬁciency (M ± m, n = 10).
Groups of animals Functional tests SAP, mmhg DAP, mmhg Area of vascular reaction CED
Tween-80
Before test 129,2 ± 4,3 82,4 ± 5,9
0,9 ± 0,2 AH 74,1 ± 2,9 39,4 ± 3,1 1124,2 ± 63,7
NP 67,2 ± 5,1 42,9 ± 5,4 1011,8 ± 94,6
Methionine 3g/kg
Before test 118,9 ± 10,1 76,6 ± 7,2
3,3 ± 0,3∗ AH 80,1 ± 2,9 41,4 ± 2,3 854,6 ± 61,4∗
NP 72,3 ± 6,7 45,9 ± 4,3 2820,2 ± 210,4∗
Methionine 3g/kg + L-norvaline 10mg/kg
Before test 129,4 ± 2,8∗∗ 72,6 ± 5,4∗∗
1,4 ± 0,1∗∗ AH 91,0 ± 3,1 47,1 ± 1,8∗∗ 920,9 ± 7,8∗
NP 123,8 ± 4,5 63,4 ± 5,0∗∗ 1214,7 ± 128,4∗∗
∗P<. 05 in comparison with intact group of animals; ∗∗P<. 05 in comparison with metionine group.
L-NAME and methionine introduction, the special coeﬃ-
cient of endothelial dysfunction (CED) [12] is applied in
our laboratory. It characterizes the endothelial dysfunction
degree.
In each animal in each group, CED was measured.
After modeling of NOS blockade, In the group of animals
receiving L-NAME, CED was equal to 5,4 ± 0,6 while in
group of intact animals CED was 1,1 ± 0,1. In the animals
receiving L-norvaline against introduction ofL-NAME,CED
was 2,1 ± 0,2, coming a value close to that group of intact
animals (Table 1).Inanimals receivingmethionine,CEDwas
3,3 ± 0,3. In the animals receiving Tween-80 CED was equal
to 0,9 ± 0,2, and in animals receiving L-norvaline against
methionine, CED was 1,4 ± 0,1 (Table 2).
4.Discussion
In conditions of normally functioning endothelium, the bal-
ance between vasoconstriction and vasodilatation factors is
supported. The basic vasodilatation agent in endothelium is
NO. Infringement of the given balance leads to development
of endothelial dysfunction. L-arginine serves as a source of
NO in a cell. Inhibitors of arginase, suppressing activity
of the given enzyme, promote NO biosynthesis increase,
preventing the development of endothelial dysfunction.
Application of L-norvaline promotes suppression of activity
Arginase
Ornithine
L-arginin Citrulline
No
Urea
L-norvaline
Figure 1: The mechanism of action of arginase inhibitors.
of arginase enzyme which allows for a raise in L-arginine
stocks. Expressed endothelium-protective action is provided
ﬁrst of all with increase in stocks of endogenous L-arginine
by infringement of its hydrolysis into ornithine and urea
(Figure 1) ,w h i c hp r o v e st ob et r u eb yo b v i o u sd e c r e a s e
of CED in animals. In connection with the aforesaid, it is
possible to speak about endothelium-protective action of
the given group of substances and the prospect for their
combined application with L-arginine and the preparations
traditionally applied for cardiovascular disease treatment.4 International Journal of Hypertension
5.Conclusion
The present research shows expressed endothelium-pro-
tective property of arginase inhibitor, L-norvaline, charac-
terized by decrease of coeﬃcient of endothelial dysfunction
and the approached its application to a group of intact
animals. In other words, L-norvaline prevents the develop-
ment of systemic endothelial dysfunctions in L-NAME- and
methionine-induced NO deﬁciency.
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